British American Tobacco p.l.c.
10
February 2025
Board and
Committee Changes
Uta Kemmerich-Keil will join the
Board of British American Tobacco p.l.c. (BAT) as an independent
Non-Executive Director with effect from 17 February 2025 and will
be appointed as a member of the Audit and Nominations
Committees.
Uta previously held the role of
Chief Executive Officer, Personal Healthcare International at
P&G from 2018 to 2020, and prior to that spent 19 years at
Merck Group where she held several roles including Chief Executive
Officer, Consumer Health Division, Chief Executive Officer,
Allegropharma and Global Business Unit Head, Allergy as well as
Head of Corporate M&A, Treasury and Finance. Prior to joining
Merck Group, Uta was a Senior Financial Auditor at Hoechst AG.
Uta currently serves as a member of the Supervisory
Board and Chair of the Audit Committee at Beiersdorf.
Commenting on the appointment, Luc
Jobin, Chair of the Board, said: "I am pleased to welcome Uta
Kemmerich-Keil to our Board. Her strong general management
background in regulated industries, combined with her experience in
consumer, digital and strategic transformation will be beneficial
as BAT continues on its ambition to build a Smokeless
World".
BAT also announces that it has
received notice from Murray S. Kessler, Non-Executive Director of
the Company, that he will step down from the Board with effect from
17 February 2025 to focus on his recent appointment as Chief
Executive Officer of Wellington International LLC.
Commenting on Murray's departure,
Luc Jobin, said: "I would like to thank Murray for his contribution
during his tenure and his valuable insights to the Board. We wish
him well in this new endeavour."
In light of the above changes, a review of the
Company's Board Committees membership has been undertaken. Karen
Guerra, a Non-Executive Director of the Company, will join the
Remuneration Committee and step down from the Audit Committee with
effect from 10 February 2025.
The Company's Audit Committee and Remuneration
Committee membership as at 17 February 2025 is set out
below:
|
Audit
Committee
|
Remuneration
Committee
|
|
Darrell Thomas (Committee Chair)
|
Kandy Anand (Committee Chair)
|
|
Holly Keller Koeppel
|
Karen Guerra
|
|
Uta Kemmerich-Keil
|
Serpil Timuray
|
|
Véronique Laury
|
|
Enquiries:
Media Centre
+44 (0) 20 7845 2888 (24 hours) |
@BATplc
Investor Relations
Victoria Buxton: +44 (0)20 7845 2012 |
IR_team@bat.com
Additional
information
1. This announcement is made in
compliance with the Company's obligations under UKLR
6.4.6.
2. In accordance with the Listing Rules,
Uta Kemmerich-Keil is Board member of Beiersdorf AG and Karo
Healthcare AB (formerly listed as Karo Pharma AB). She was
previously a Board member of Biotest AG, Affimed N.V.. There are no
additional matters that would require disclosure under UKLR 6.4.8
in respect of this appointment.
